



I. Epidemiological profile

Population (UN)	2016	%
Number of active foci	0	
Number of people living within active foci	0	0
Malaria-free (0 cases)	6,725,000	100
Total	6,725,000	

Parasites and vectors	
Plasmodium species:	<i>P. falciparum</i> (0%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An. darlingi</i> , <i>An. albitalis</i>
Reported confirmed cases (health facility):	0
Imported cases	10
Reported deaths:	0

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	No	-
	ITNs/ LLINs distributed to all age groups	No	-
IRS	IRS is recommended	Yes	1957
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	No	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	1957
	Malaria diagnosis is free of charge in the public sector	Yes	1957
Treatment	ACT is free of charge for all ages in public sector	Yes	2005
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2014
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	1957
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	No	1957
	System for monitoring adverse reactions to antimalarials exists	Yes	-
Surveillance	ACD for case investigation (reactive)	Yes	1957
	ACD of febrile cases at community level (pro-active)	Yes	1957
	Mass screening is undertaken	Yes	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	1957
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	1957
	Foci and case investigation undertaken	Yes	1957
	Case reporting from private sector is mandatory	Yes	-

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of <i>P. falciparum</i>	AL+PQ	-
Treatment failure of <i>P. falciparum</i>	-	-
Treatment of severe malaria	AS	-
Treatment of <i>P. vivax</i>	CQ+PQ	-
Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)
Type of RDT used		-

Therapeutic efficacy tests (clinical and parasitological failure, %)


Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species

Insecticide resistance tests (mosquito mortality, %)


Insecticide class	Years	Min	Mean	Max	No. of sites	Species

III. Financing

Sources of financing




Government expenditure by intervention in 2016




IV. Coverage


Coverage of ITN and IRS




Cases tested



Cases treated




Cases tracked




V. Impact

Confirmed malaria cases per 1000 and ABER



Number of malaria cases



Notes:

Reported confirmed cases and reported deaths are indigenous only